1. Pursuant to section 24 of the Veterans’ Support Act 2014, the Minister for Veterans gives notice of the amendment of 124 Statements of Principles under the Veterans’ Support Regulations 2014.
2. The amendments take effect on the day after the publication of this notice.
3. The amendments comprise a change to the definition of “cumulative equivalent dose” in clause 9, or in clause 1 of Schedule 1, as applicable in the Statements of Principles listed in paragraph 4 below. The new definition reads:
1. “cumulative equivalent dose means the total dose of ionising radiation received by the particular organ or tissue from external exposure, internal exposure or both, apart from normal background radiation exposure in Australia, calculated in accordance with the methodology set out in Guide to calculation of ‘cumulative equivalent dose’ for the purpose of applying ionising radiation factors contained in Statements of Principles determined under Part XIA of the Veterans’ Entitlement Act 1986 (Cth), Australian Radiation Protection and Nuclear Safety Agency, as in force on 2 August 2017”.
4. The amendments are compiled with the following Statements of Principles:

1. acoustic neuroma, 29/2011 & 30/2011

   acquired cataract, 87/2016 & 88/2016

   acute lymphoblastic leukaemia, 75/2012 & 76/2012

   acute myeloid leukaemia, 71/2015 & 72/2015

   adenocarcinoma of the kidney, 9/2013 & 10/2013

   Alzheimer-type dementia, 22/2010 (Reasonable hypothesis version only)

   angle-closure glaucoma, 25/2012 & 26/2012

   aortic stenosis, 21/2013 & 22/2013

   atherosclerotic peripheral vascular disease, 23/2012 & 24/2012

   benign neoplasm of the eye and adnexa, 41/2016 & 42/2016

   cardiomyopathy, 85/2015 & 86/2015

   carotid arterial disease, 37/2012 & 38/2012

   cerebral meningioma, 19/2009 & 20/2009

   cerebrovascular accident, 65/2015 & 66/2015

   chronic gastritis and chronic gastropathy, 25/2013 & 26/2013

   chronic myeloid leukaemia, 47/2014 & 48/2014

   chronic pancreatitis, 104/2011 & 105/2011

   cirrhosis of the liver, 1/2017 (Reasonable hypothesis version only)

   erectile dysfunction, 43/2013 & 44/2013

   external burn, 110/2015 & 111/2015

   fibrosing interstitial lung disease, 53/2013 & 54/2013

   gastric ulcer and duodenal ulcer, 61/2015 & 62/2015

   goitre, 23/2013 & 24/2013

   Graves’ disease, 33/2013 & 34/2013

   Hashimoto’s thyroiditis, 31/2013 & 32/2013

   heart block, 1/2014 & 2/2014

   hypothyroidism, 29/2013 & 30/2013

   ischaemic heart disease, 1/2016 & 2/2016

   malignant neoplasm of the bile duct, 69/2015 & 70/2015

   malignant neoplasm of the bladder, 96/2011 & 97/2011

   malignant neoplasm of the bone and articular cartilage, 106/2011 & 107/2011

   malignant neoplasm of the brain, 85/2016 & 86/2016

   malignant neoplasm of the breast, 96/2014 & 97/2014

   malignant neoplasm of the cerebral meninges, 21/2009 & 22/2009

   malignant neoplasm of the colorectum, 37/2013 & 38/2013

   malignant neoplasm of the endometrium, 11/2016 & 12/2016

   malignant neoplasm of the gallbladder, 89/2015 & 90/2015

   malignant neoplasm of the liver, 21/2011 & 22/2011

   malignant neoplasm of the lung, 92/2014 & 93/2014

   malignant neoplasm of the oesophagus, 120/2015 & 121/2015

   malignant neoplasm of the ovary, 70/2009 & 71/2009

   malignant neoplasm of the renal pelvis and ureter, 98/2011 & 99/2011

   malignant neoplasm of the salivary gland, 57/2015 & 58/2015

   malignant neoplasm of the stomach, 58/2014 & 59/2014

   malignant neoplasm of the thyroid gland, 39/2014 & 40/2014

   malignant neoplasm of unknown primary site, 80/2014 & 81/2014

   mesothelioma, 104/2015 & 105/2015

   multiple sclerosis, 100/2011 (Reasonable hypothesis version only)

   myelodysplastic syndrome, 73/2015 & 74/2015

   myeloma, 69/2012 (Reasonable hypothesis version only)

   narcolepsy, 7/2014 & 8/2014

   neoplasm of the pituitary gland, 53/2015 (Reasonable hypothesis version only)

   non-aneurysmal aortic atherosclerotic disease, 15/2012 & 16/2012

   Non-Hodgkin’s lymphoma, 28/2010 (Reasonable hypothesis version only)

   non-melanotic malignant neoplasm of the skin, 7/2016 & 8/2016

   open-angle glaucoma, 27/2012 & 28/2012

   optochiasmatic arachnoiditis, 57/2016 & 58/2016

   osteomyelitis, 90/2014 & 91/2014

   otitis externa, 58/2012 & 59/2012

   otitis media, 51/2014 & 52/2014

   peritoneal adhesions, 3/2016 & 4/2016

   renal artery atherosclerotic disease, 102/2011 & 103/2011

   soft tissue sarcoma, 5/2015 & 6/2015

   tinnitus, 33/2012 & 34/2012

   trigeminal neuropathy, 79/2015 & 80/2015

5. These amended Statements of Principles are available on the website of the Australian Government Repatriation Medical Authority: www.rma.gov.au.

Dated at Wellington this 29th day of November 2017.

Hon RON MARK, Minister for Veterans.